Silvy Laporte
Overview
Explore the profile of Silvy Laporte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
1648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre M, Meneveau N, et al.
Lancet
. 2025 Mar;
405(10480):725-735.
PMID: 40023651
Background: In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to...
2.
Barret L, Liaigre L, Hlavaty A, Giai J, Laporte S, Ollier E, et al.
J Clin Epidemiol
. 2024 Dec;
179():111651.
PMID: 39724990
Objectives: To describe the priors and decision thresholds in phase 2 and 3 randomized controlled trials (RCTs) evaluating drug efficacy using Bayesian methods. Study Design And Setting: A systematic review...
3.
Godier A, Lasne D, Pernod G, Blais N, Bonhomme F, Bounes F, et al.
Anaesth Crit Care Pain Med
. 2024 Oct;
:101446.
PMID: 39447869
Background: Any surgical procedure carries a risk for venous thromboembolism (VTE), albeit variable. Improvements in medical and surgical practices and the shortening of care pathways due to the development of...
4.
Escal J, Lanoiselee J, Poenou G, Zufferey P, Laporte S, Mismetti P, et al.
Fundam Clin Pharmacol
. 2024 Feb;
38(4):674-684.
PMID: 38350629
Background: Since the late 2000s, Europe has granted approval for various thrombotic risk-related uses of direct oral anticoagulants (DOACs). Unlike traditional anticoagulants, DOACs do not necessitate routine coagulation monitoring. Nevertheless,...
5.
Mottier D, Girard P, Couturaud F, Lacut K, Le Moigne E, Paleiron N, et al.
NEJM Evid
. 2024 Feb;
2(8):EVIDoa2200332.
PMID: 38320142
BACKGROUND: Admission to the hospital is a major risk factor for the development of venous thromboembolism (VTE). Whether thromboprophylaxis with low-molecular-weight heparin prevents symptomatic VTE in medically ill, hospitalized older...
6.
Locher C, Laporte S, Derambure P, Chassany O, Girault C, Avakiantz A, et al.
Therapie
. 2023 Dec;
79(1):111-121.
PMID: 38103949
Clinical trials often last several months or even several years. As the trial progresses, it can be tempting to find out whether the data obtained already answers the question posed...
7.
Mahe I, Mayeur D, Couturaud F, Scotte F, Benhamou Y, Benmaziane A, et al.
Arch Cardiovasc Dis
. 2023 Dec;
117(1):29-44.
PMID: 38092578
Venous thromboembolism (VTE) is a frequent and potentially fatal complication in patients with cancer. During the initial period after the thromboembolic event, a patient receiving anticoagulant treatment is exposed both...
8.
Laporte S, Benhamou Y, Bertoletti L, Frere C, Hanon O, Couturaud F, et al.
Arch Cardiovasc Dis
. 2023 Dec;
117(1):45-59.
PMID: 38065754
Although all patients with cancer-associated thrombosis (CAT) have a high morbidity and mortality risk, certain groups of patients are particularly vulnerable. This may expose the patient to an increased risk...
9.
Carton L, Bordy R, Totoson P, Laforgue E, Pelerin J, Portier-Feunteun T, et al.
Therapie
. 2023 Nov;
79(4):435-441.
PMID: 38008601
Objective: The disputatio is a pedagogical method existing since the Middle-Ages where students had to debate about a question asked by a "master", exercising their thinking and oratory skills. To...
10.
Locher C, Laporte S, Derambure P, Chassany O, Girault C, Avakiantz A, et al.
Therapie
. 2023 Nov;
79(1):99-110.
PMID: 37985309
No abstract available.